

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

PC02200

315379

Licensee 1. Missouri Cancer Care, P.C. 2. 1078 Wentzville Parkway Wentzville, MO 63385	In accordance with letter dated April 16, 2006, 3. License number 24-32414-01 is amended in its entirety to read as follows: 4. Expiration date September 30, 2012 5. Docket No. 030-36080 Reference No.
---	--

- | | | |
|---|---|--|
| 6. Byproduct, source, and/or special nuclear material

A. Yttrium-90 permitted by 10 CFR 35.300 | 7. Chemical and/or physical form

A. Monoclonal antibody (Zevalin™) | 8. Maximum amount that licensee may possess at any one time under this license

A. 300 millicuries |
|---|---|--|

9. Authorized Use:
 A. Any therapy procedure permitted by 10 CFR 35.300

10. Licensed material shall be used only at the licensee's facilities located at 1092 Wentzville Parkway, Wentzville, Missouri.

11. The Radiation Safety Officer for this license is Loretta A. Lewandowski, Ph.D.

12. Licensed material is only authorized for use by, or under the supervision of:

- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 B. The following individuals are authorized users for medical use as indicated:

Authorized Users

John Bedwinek, M.D.

Ana C. Botero, M.D.

Material and Use

Yttrium-90 monoclonal antibody (Zevalin™)

Yttrium-90 monoclonal antibody (Zevalin™)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number


24-32414-01

Docket or Reference Number

030-36080

Amendment No. 02

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated July 16, 2002, with attachments, (excluding QMP); and,
 - B. Letters dated July 30, 2002, and August 23, 2002; and,
 - C. Letter received July 26, 2002.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JUN 28 2006By Toye L. SimmonsToye L. Simmons
Materials Licensing Branch
Region III